BioWorld

Oct. 14, 2004

AtheroGenics Drops AGIX-4207 After Phase II Miss In Arthritis

AtheroGenics Inc. is discontinuing the development of one of its investigational drugs following a Phase II failure. (BioWorld Today) Read More

Panel: Novelty, Strong Science Keys To Snagging VC Funding

VistaGen, Sanwa Studying ESCs For Use In Diabetes

Halozyme Privately Brings In $14M For Hyaluronidase

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...